Zydus receives final approval from the USFDA for Carbamazepine Extended-Release Tablets USP

Zydus receives final approval from the USFDA for Carbamazepine Extended-Release Tablets USP ______________________________________________________________ Ahmedabad, 08 February, 2019 Zydus Cadila has received the final approval from the USFDA to market Carbamazepi ne Extended-Release Tablets USP (US RLD – Tegretol XR), 100 mg, 200 mg, and 400 mg. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. Carbamazepine is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve activity. This medication is used to treat certain types of seizures (partial, generalized tonic- clonic, mixed) and certain types of nerve pain (trigeminal and glossopharyngeal neuralgia). The group now has 248 approvals and has so far filed over 35 0 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare the rapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗